Ezlopitant, also known CJ-11,974; is NK1 receptor antagonist. It has antiemetic and antinociceptive effects. Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued. References: MuA±oz M, CoveA±as R. Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf. 2013 Sep;12(5):673-85. doi: 10.1517/14740338.2013.804059. Epub 2013 May 25. PubMed PMID: 23706125.

纯度：≥98%

CAS：147116-64-1